Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma

Badruddoja Michael A.; Pazzi Marjorie; Sanan Abhay; Schroeder Kurt; Kuzma Kevin; Norton Thomas; Scully Thomas; Mahadevan Daruka; Ahmadi Michael Malek

首页> 外文期刊>Cancer chemotherapy and pharmacology. >Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma

【24h】

Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma

机译：双儿性替莫唑胺类研究成人患者复发性胶质母细胞瘤的成人患者的II期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Bevacizumab is an active anti-angiogenic agent in the treatment of recurrent glioblastoma. Temozolomide can prolong survival in patients with newly diagnosed glioblastoma. At recurrence, alternate dosing of temozolomide has shown to further deplete methyl-guanine-methyltransferase (MGMT) conferring added activity for patients who have progressed on the standard dosing regimen. In this study, bevacizumab plus biweekly temozolomide was evaluated for efficacy in adult patients with recurrent glioblastoma.

机译：贝伐单抗是治疗复发性胶质母细胞瘤的有效抗血管生成药物。替莫唑胺可以延长新诊断的胶质母细胞瘤患者的生存期。复发时，替莫唑胺的交替给药显示会进一步消耗甲基鸟嘌呤甲基转移酶（MGMT），从而增加标准给药方案进展患者的活性。在这项研究中，贝伐单抗加两周一次的替莫唑胺对复发性胶质母细胞瘤成年患者的疗效进行了评估。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2017年第4期|共7页
作者
Badruddoja Michael A.; Pazzi Marjorie; Sanan Abhay; Schroeder Kurt; Kuzma Kevin; Norton Thomas; Scully Thomas; Mahadevan Daruka; Ahmadi Michael Malek;
展开▼
作者单位

Ctr Neurosci 2450 E River Rd Tucson AZ 85718 USA;

Ctr Neurosci 2450 E River Rd Tucson AZ 85718 USA;

Ctr Neurosci 2450 E River Rd Tucson AZ 85718 USA;

Ctr Neurosci 2450 E River Rd Tucson AZ 85718 USA;

Genentech Inc DNA Way San Francisco CA 94080 USA;

Ctr Neurosci 2450 E River Rd Tucson AZ 85718 USA;

Ctr Neurosci 2450 E River Rd Tucson AZ 85718 USA;

Univ Arizona Ctr Canc 1515 N Campbell Ave Tucson AZ 85724 USA;

Ctr Neurosci 2450 E River Rd Tucson AZ 85718 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Glioblastoma; Temozolomide; Bevacizumab; Methyl-guanine; Methyltransferase;

机译：胶质母细胞瘤;替替莫唑胺;bevacizumab;甲基 - 鸟嘌呤;甲基转移酶;

相似文献

外文文献
中文文献

1. Combination therapy of long-term tumor treating fields with temozolomide and bevacizumab prolongs survival in multifocal glioblastoma diagnosed patient: a case report [J] . Damir Nizamutdinov, Kaiyang Feng, Amanda Johnson, 转化神经科学电子杂志（英文） . 2019,第001期
2. Combination therapy of long-term tumor treating fields with temozolomide and bevacizumab prolongs survival in multifocal glioblastoma diagnosed patient: a case report [J] . Damir Nizamutdinov, Kaiyang Feng, Amanda Johnson, 转化神经科学电子杂志（英文） . 2019,第001期
3. Complete response with fotemustine and bevacizumab after early progression following radiotherapy and temozolomide treatment in patient with glioblastoma multiforme [J] . Ovidio Fernández Calvo, María Eva Pérez López, Jesús García Gómez 癌症转移与治疗（英文版） . 2015,第001期
4. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (vol 80, pg 715, 2017) [J] . Badruddoja Michael A., Pazzi Marjorie, Sanan Abhay, Cancer chemotherapy and pharmacology. . 2018,第1期

机译：双儿性替莫替洛米德的II期研究加上成人胶质细胞瘤的成人患者（Vol 80，PG 715,2017）
5. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma [J] . Badruddoja Michael A., Pazzi Marjorie, Sanan Abhay, Cancer chemotherapy and pharmacology. . 2017,第4期

机译：双儿性替莫唑胺类研究成人患者复发性胶质母细胞瘤的二孢子蛋白
6. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma [J] . J. M. Sepúlveda, C. Belda-Iniesta, M. Gil-Gil, Clinical and Translational Oncology . 2015,第9期

机译：贝伐单抗联合替莫唑胺在复发性胶质母细胞瘤患者中的可行性和毒性的II期研究
7. MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks [C] . Lichy Han, Maulik R. Kamdar Pacific Symposium on Biocomputing . 2018

机译：使用卷积经常性神经网络预测胶质母细胞瘤患者中的甲基化状态的MRI
8. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
9. ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS [O] . Karan Dixit, Priya Kumthekar, Timothy Kruser, 2017

机译：ACTR-88。 II期研究贝伐单抗和替莫唑胺加维持性替莫唑胺和贝伐西单抗维持治疗高放疗型胶质瘤的疗效
10. Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma [O] . Michael A. Badruddoja, Marjorie Pazzi, Abhay Sanan, 2017

机译：校正：二期替补术治疗成人患者的双儿赛替莫替莫替换症
11. Phase 1 trial of intravenous boronophenylalanine-fructose complex in patients with glioblastoma multiforme [R] . Bergland, R. , Elowitz, E. , Chadha, M. , 1996

机译：多形性胶质母细胞瘤患者静脉注射硼苯丙氨酸 - 果糖复合物的1期试验

Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma

摘要

著录项

相似文献

相关主题

期刊订阅